TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6% – Here’s What Happened

TuHURA Biosciences (NASDAQ:HURA) shares traded down 2.6% during trading on Thursday . The company traded as low as $4.66 and last traded at $4.92. 320,091 shares were traded during trading, an increase of 42% from the average session volume of 224,917 shares. The stock had previously closed at $5.05.

Wall Street Analyst Weigh In

Several analysts have commented on HURA shares. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th. Maxim Group started coverage on shares of TuHURA Biosciences in a research report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 target price for the company. Finally, Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price for the company.

TuHURA Biosciences Stock Performance

The business has a 50-day moving average of $4.73.

Institutional Trading of TuHURA Biosciences

A hedge fund recently bought a new stake in TuHURA Biosciences stock. Apollon Wealth Management LLC acquired a new position in TuHURA Biosciences (NASDAQ:HURA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 61,772 shares of the company’s stock, valued at approximately $253,000. Apollon Wealth Management LLC owned about 0.15% of TuHURA Biosciences at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.